Research output per year
Research output per year
Personal profile
Expertises
For NSCLC, especially for genomic defined subtypes (ALK positive and EGFR mutated). Besides for Malign Pleural Mesotheliom, SCLC/NEC and palliative care.
Main research areas
Genomic defined NSCLC
Current research
Genomic research project about molecular status af ALK positive NSCLC
Potential conflicts of interest
Had in the past received honoraria from Pfizer A/S. No conflicts curently.
Fingerprint
Dive into the research topics where Edyta Maria Urbanska is active. These topic labels come from the works of this person. Together they form a unique fingerprint.
- 1 Similar Profiles
Collaborations and top research areas from the last five years
Recent external collaboration on country/territory level. Dive into details by clicking on the dots or
-
Alectinib impressively enters the adjuvant setting for early-stage ALK-rearranged non-small cell lung cancer and outperforms chemotherapy-let's define who benefits the most
Santoni-Rugiu, E., Sørensen, J. B. & Urbanska, E. M., 28 Feb 2025, In: Translational lung cancer research. 14, 2, p. 310-313 4 p.Research output: Contribution to journal › Comment/debate › Research › peer-review
-
Can We Refine Criteria for the First-Line Treatment for Patients With Advanced ALK-Positive NSCLC in the Real World?
Urbanska, E. M., Sørensen, J. B. & Santoni-Rugiu, E., Jun 2025, In: Journal of Thoracic Oncology. 20, 6, p. e71-e72Research output: Contribution to journal › Comment/debate › Research › peer-review
-
Targeting of arachidonic acid-modulated autophagy to enhance the sensitivity of ROS1 + or ALK + non-small cell lung cancer to crizotinib therapy
Jie, H., Lai, H., Wang, Z., Yi, M., Liu, Y., Urbanska, E. M., Santoni-Rugiu, E., Wei, S., Chen, Y., Li, C., Wang, T., Luo, N., Liu, L., Deng, S. & Guo, C., 31 Mar 2025, In: Translational lung cancer research. 14, 3, p. 878-896 19 p.Research output: Contribution to journal › Journal article › Research › peer-review
1 Citation (Scopus) -
ALK-tyrosine kinase inhibitor intrinsic resistance due to de novo MET-amplification in metastatic ALK-rearranged non-small cell lung cancer effectively treated by alectinib-crizotinib combination-case report
Urbanska, E. M., Grauslund, M., Berger, S. M. S., Costa, J. C., Koffeldt, P. R., Sørensen, J. B. & Santoni-Rugiu, E., 30 Sept 2024, In: Translational lung cancer research. 13, 9, p. 2453-2462 10 p.Research output: Contribution to journal › Journal article › Research › peer-review
1 Citation (Scopus) -
A rare case report of a primary lung cancer comprising adenocarcinoma and atypical carcinoid tumor, with the carcinoid component harboring EML4-ALK rearrangement
Hu, W., Zhao, J., Wang, G., Wang, Q., Deng, M., Shen, J., Hofman, P., Urbanska, E. M., Santoni-Rugiu, E., Christopoulos, P., Ramirez, R. A., Hida, T., Lu, X. & He, B., 31 May 2024, In: Translational lung cancer research. 13, 5, p. 1150-1162 13 p.Research output: Contribution to journal › Journal article › Research › peer-review
1 Citation (Scopus)